Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2005

01-12-2005

Improved Survival Associated With Postoperative Wound Infection in Dogs Treated With Limb-Salvage Surgery for Osteosarcoma

Authors: B. Duncan X. Lascelles, BVSc, PhD, William S. Dernell, DVM, MS, Maria T. Correa, MSc, PhD, Mary Lafferty, Chad M. Devitt, DVM, MS, Charles A. Kuntz, DVM, MS, Rodney C. Straw, DVM, MS, Stephen J. Withrow, DVM

Published in: Annals of Surgical Oncology | Issue 12/2005

Login to get access

Abstract

Background

Limb-salvage surgery and adjuvant chemotherapy are performed as a treatment of appendicular osteosarcoma in dogs. Approximately 50% of dogs that undergo limb-salvage surgery develop postoperative surgical wound infections. Postoperative surgical infections may affect survival in cancer patients. The purposes of this study were to examine the effect of surgical wound infection on survival, local recurrence, and metastasis in relation to other prognostic factors for dogs with spontaneous osteosarcoma treated with limb-salvage surgery.

Methods

Forty-seven client-owned dogs with osteosarcoma of the distal radius were treated with limb-salvage surgery and adjuvant chemotherapy—either carboplatin or carboplatin and doxorubicin. Hazard ratios were estimated by using the Cox proportional hazard model, and survival functions were estimated by using the Kaplan-Meier product-limit life-table method.

Results

Of the 47 dogs in this study, 32 (68%) developed a postoperative wound infection. Infection, dog weight, and extent of the primary tumor (percentage of length) significantly affected survival, and infection and percentage of length significantly affected time to metastasis. None of the variables considered in this study affected local recurrence. Dogs that were diagnosed with an infection were less likely to die (hazard ratio, .446), and dogs with greater body weight and greater percentage length involvement were more likely to die (hazard ratios of 3.37 and 3.66, respectively).

Conclusions

In dogs with osteosarcoma treated with limb-salvage surgery, infection has a positive influence on survival, as does a smaller initial length of radius involved and lower body weight.
Literature
1.
Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997;79:1343–50CrossRefPubMed
2.
Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop 1991;270:159–68
3.
Berg J, Weinstein MJ, Schelling SH, Rand WM. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987–1990). J Am Vet Med Assoc.1992;200:2005–8PubMed
4.
Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555–60PubMed
5.
Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76–81PubMed
6.
LaRue SM, Withrow SJ, Powers BE, et al. Limb-sparing treatment for osteosarcoma in dogs. J Am Vet Med Assoc 1989;195:1734–44PubMed
7.
Shapiro W, Fossum T, Kitchell B, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988;192:507–11PubMed
8.
Spodnick G, Berg J, Rand W, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992;200:995–9PubMed
9.
Maulin G, Matus R, Withrow S. Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988;2:177–80
10.
Straw RC, Withrow SJ. Limb-sparing surgery versus amputation for dogs with bone tumors. Vet Clin North Am Small Anim Pract 1996;26:135–43PubMed
11.
Thrall DE, Withrow SJ, Powers BE, et al. Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay. Int J Radiat Oncol Biol Phys 1990;18:1351–7PubMed
12.
Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64:529–64CrossRefPubMed
13.
Schantz SP, Skolnik EM, O’Neill JV. Improved survival associated with postoperative wound infection in laryngeal cancer: an analysis of its therapeutic implications. Otolaryngol Head Neck Surg 1980;88:412–7PubMed
14.
Sensenig DM, Rossi NP, Ehrenhaft JL. Pulmonary resection for bronchogenic carcinoma in geriatric patients. Ann Thorac Surg 1966;2:508–13PubMedCrossRef
15.
Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med 1972;287:1013–7PubMedCrossRef
16.
Grandis JR, Snyderman CH, Johnson JT, et al. Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer. Cancer 1992;70:2166–70PubMed
17.
Jackson RM, Rice DH. Wound infections and recurrence in head and neck cancer. Otolaryngol Head Neck Surg 1990;102:331–3PubMed
18.
Papachristou DN, Fortner JG. Effect of postoperative wound infection on the course of stage II melanoma. Cancer 1979;43:1106–11PubMed
19.
Higuchi Y. Antitumor effect of Streptococcus pyogenes by inducing hydrogen peroxide production. Jpn J Cancer Res 1996;87:1271–9PubMed
20.
Withrow SJ, Liptak JM, Straw RC, et al. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. Ann Surg Oncol 2004;11:705–13CrossRefPubMed
21.
Straw RC, Powers BE, Withrow SJ, et al. The effect of intramedullary polymethylmethacrylate on healing of intercalary cortical allografts in a canine model. J Orthop Res 1992;10:434–9CrossRefPubMed
22.
Dernell W, Withrow SJ, Straw RC, et al. Clinical response to antibiotic impregnated polymethyl methacrylate bead implantation of dogs with severe infections after limb sparing with allograft replacement; 18 cases (1994–1996). Vet Comp Orthop Traumatol 1998;11:94–9
23.
Sturgis EM, Congdon DJ, Mather FJ, Miller RH. Perioperative transfusion, postoperative infection, and recurrence of head and neck cancer. South Med J 1997;90:1217–24PubMed
24.
Kressner U, Graf W, Mahteme H, et al. Septic complications and prognosis after surgery for rectal cancer. Dis Colon Rectum 2002;45:316–21CrossRefPubMed
25.
Garzotto CK, Berg J, Hoffmann WE, Rand WM. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 2000;14:587–92CrossRefPubMed
26.
Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423–31PubMed
27.
Powers BE, Withrow SJ, Thrall DE, et al. Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer 1991;67:126–34PubMed
28.
Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12:2699–705PubMed
29.
Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848–58PubMed
30.
Ehrhart N, Dernell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990–1996). J Am Vet Med Assoc 1998;213:1002–6PubMed
31.
Dick HM, Strauch RJ. Infection of massive bone allografts. Clin Orthop 1994(306):46–53
32.
Mankin HJ, Gebhardt MC, Jennings LC, et al. Long-term results of allograft replacement in the management of bone tumors. Clin Orthop 1996(324):86–97
33.
Gebhardt MC, Flugstad DI, Springfield DS, Mankin HJ. The use of bone allografts for limb salvage in high-grade extremity osteosarcoma. Clin Orthop 1991(270):181–96
34.
Brown DC, Conzemius MG, Shofer F, Swann H. Epidemiologic evaluation of postoperative wound infections in dogs and cats. J Am Vet Med Assoc 1997;210:1302–6PubMed
35.
Dernell WS, Withrow SJ, Straw RC, et al. Intracavitary treatment of soft tissue sarcomas in dogs using cisplatin in a biodegradable polymer. Anticancer Res 1997;17:4499–505PubMed
36.
Ehrhart N, Dernell WS, Ehrhart EJ, et al. Effects of a controlled-release cisplatin delivery system used after resection of mammary carcinoma in mice. Am J Vet Res 1999;60:1347–51PubMed
37.
Mnaymneh W, Malinin TI, Lackman RD, et al. Massive distal femoral osteoarticular allografts after resection of bone tumors. Clin Orthop 1994(303):103–15
38.
Withrow SJ, Straw RC, Brekke JH, et al. Slow release adjuvant cisplatin for treatment of metastatic canine osteosarcoma. Eur J Exp Musculoskel Res 1995;4:105–10
39.
Misdorp W, Hart AA. Some prognostic and epidemiologic factors in canine osteosarcoma. J Natl Cancer Inst 1979;62:537–45PubMed
40.
Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am 1990;72:643–53PubMed
41.
Bech-Nielsen S, Brodey RS, Fidler IJ, et al. The effect of BCG on in vitro immune reactivity and clinical course in dogs treated surgically for osteosarcoma. Eur J Cancer 1977;13:33–41PubMed
42.
Eilber FR, Townsend C, Morton DL. Osteosarcoma. Results of treatment employing adjuvant immunotherapy. Clin Orthop 1975(111):94–100PubMed
43.
Owen LN, Bostock DE. Effects of intravenous BCG in normal dogs and in dogs with spontaneous osteosarcoma. Eur J Cancer 1974;10:775–80PubMed
44.
Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666–70PubMed
45.
Oettgen HF, Carswell EA, Kassel RL, et al. Endotoxin-induced tumor necrosis factor. Recent Results Cancer Res 1980;75:207–12PubMed
46.
Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999;17:37–41PubMed
47.
Watanabe N, Niitsu Y, Yamauchi N, et al. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients. Immunopharmacol Immunotoxicol 1988;10:53–65PubMed
48.
Suzuki K, Tsuge I, Ito Y, et al. Histological effect of intranodal injection of the streptococcal preparation OK-432 for cervical lymph node metastases of malignant head and neck tumors. Acta Otolaryngol Suppl 1996;525:125–8PubMed
49.
Kimura T, Suzuki K, Motai H, et al. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer. Acta Otolaryngol Suppl 1996;525:135–41PubMed
50.
Taradi M, Urano M, Taradi SK, Maruyama Y. Augmentation of mouse natural killer cell activity by combined hyperthermia and streptococcal preparation, OK-432 (Picibanil) treatment. Int J Hyperthermia 1991;7:653–65PubMed
51.
Ozaki S, Suginoshita T, Watanabe T, Obayashi H. Mechanism of tumoricidal activity of OK-432-specific L3T4+ Lyt2− T-cells. Cancer Res 1990;50:4630–4PubMed
52.
Asano T, McWatters A, An T, et al. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther 1994;268:1032–9PubMed
53.
Asano T, Kleinerman ES. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J Immunother 1993;14:286–92PubMed
54.
Kurzman ID, MacEwen EG, Rosenthal RC, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995;1:1595–601PubMed
55.
Youdim S. Resistance to tumor growth mediated by Listeria monocytogenes. Destruction of experimental malignant melanoma by LM-activated peritoneal and lymphoid cells. J Immunol 1976;116:579–84PubMed
56.
Youdim S. Destruction of experimental malignant melanoma by mediators of cellular immunity. Cancer Res 1977;37:572–7PubMed
57.
Hunter CA, Yu D, Gee M, et al. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol 2001;166:5878–81PubMed
58.
Thomas-Tikhonenko A, Hunter CA. Infection and cancer: the common vein. Cytokine Growth Factor Rev 2003;14:67–77CrossRefPubMed
59.
Scotlandi K, Serra M, Nicoletti G, et al. Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 1996;56:2434–9PubMed
60.
Mizutani Y, Bonavida B, Koishihara Y, et al. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995;55:590–6PubMed
61.
Mizutani Y, Bonavida B. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer 1993;72:809–18PubMed
62.
Walther W, Stein U. Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 1994;120:471–8CrossRefPubMed
63.
Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 1996;88:1383–92PubMed
64.
Fujisawa T, Yamaguchi Y. Postoperative immunostimulation after complete resection improves survival of patients with stage I nonsmall cell lung carcinoma. Cancer 1996;78:1892–8CrossRefPubMed
65.
Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001;90:191–9CrossRefPubMed
66.
Sandoval BA, Robinson AV, Sulaiman TT, et al. Open versus laparoscopic surgery: a comparison of natural antitumoral cellular immunity in a small animal model. Am Surg 1996;62:625–30; discussion 630–1PubMed
67.
Kutza J, Gratz I, Afshar M, Murasko DM. The effects of general anesthesia and surgery on basal and interferon stimulated natural killer cell activity of humans. Anesth Analg 1997;85:918–23PubMed
68.
Page GG, Ben-Eliyahu S, Liebeskind JC. The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun 1994;8:241–50CrossRefPubMed
69.
Knottenbelt CM, Simpson JW, Tasker S, et al. Preliminary clinical observations on the use of piroxicam in the management of rectal tubulopapillary polyps. J Small Anim Pract 2000;41:393–7PubMed
70.
Knapp DW, Chan TC, Kuczek T, et al. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995;56:801–5PubMed
71.
Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46:221–6CrossRefPubMed
72.
Knapp DW, Richardson RC, Bottoms GD, et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214–8CrossRefPubMed
73.
Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273–8PubMedCrossRef
74.
Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356–8PubMed
75.
Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001;218:1783–6PubMed
76.
Ebisuno S, Inagaki T, Kohjimoto Y, Ohkawa T. The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer 1997;80:2263–7CrossRefPubMed
77.
Seay TM, Peretsman SJ, Dixon PS. Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 1996;155:757–62PubMed
78.
Miclau T, Edin ML, Lester GE, et al. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 1998;16:509–12CrossRefPubMed
79.
Holtom PD, Pavkovic SA, Bravos PD, et al. Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro. J Orthop Res 2000;18:721–7CrossRefPubMed
80.
Sissi C, Palumbo M. The quinolone family: from antibacterial to anticancer agents. Curr Med Chem Anti-Canc Agents 2003;3:439–50CrossRefPubMed
Metadata
Title
Improved Survival Associated With Postoperative Wound Infection in Dogs Treated With Limb-Salvage Surgery for Osteosarcoma
Authors
B. Duncan X. Lascelles, BVSc, PhD
William S. Dernell, DVM, MS
Maria T. Correa, MSc, PhD
Mary Lafferty
Chad M. Devitt, DVM, MS
Charles A. Kuntz, DVM, MS
Rodney C. Straw, DVM, MS
Stephen J. Withrow, DVM
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2005
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2005.01.011

Other articles of this Issue 12/2005

Annals of Surgical Oncology 12/2005 Go to the issue

OriginalPaper

Effectiveness of Palliative Procedures for Intra-Abdominal Sarcomas

OriginalPaper

Can the Memorial Sloan-Kettering Cancer Center Nomogram Predict the Likelihood of Nonsentinel Lymph Node Metastases in Breast Cancer Patients in The Netherlands?

OriginalPaper

Older Age Independently Predicts a Lower Risk of Sentinel Lymph Node Metastasis in Breast Cancer

OriginalPaper

Herpes Simplex Virus Amplicon Delivery of a Hypoxia-Inducible Soluble Vascular Endothelial Growth Factor Receptor (sFlk-1) Inhibits Angiogenesis and Tumor Growth in Pancreatic Adenocarcinoma

OriginalPaper

Utility of Breast Magnetic Resonance Imaging in Patients With Occult Primary Breast Cancer

OriginalPaper

Evaluation of Intraoperative Autotransfusion Filtration for Hepatectomy and Pancreatectomy